2025
A Review of the Evidence Surrounding Popular Cognitive Enhancers
Draghmeh K, Elmarasi M, Fuehrlein B. A Review of the Evidence Surrounding Popular Cognitive Enhancers. Current Psychopharmacologye 2025, 13 DOI: 10.2174/0122115560363501250609121229.Peer-Reviewed Original ResearchAn evaluation of denileukin diftitox for the treatment of relapsed or refractory cutaneous T-cell lymphoma
Goyal A, Foss F. An evaluation of denileukin diftitox for the treatment of relapsed or refractory cutaneous T-cell lymphoma. Expert Opinion On Biological Therapy 2025, ahead-of-print: 1-8. PMID: 40489974, DOI: 10.1080/14712598.2025.2517853.Peer-Reviewed Original ResearchConceptsDenileukin difitoxResponse rateRefractory cutaneous T-cell lymphomaCutaneous T-cell lymphomaPlaque stage diseaseCells expressing CD25Adverse Events gradeCapillary leak syndromeElevated hepatic transaminasesImmunoregulatory T cellsT-cell lymphomaExpressing tumor cellsDiphtheria toxin AMultiple mechanisms of actionHigh response rateSezary syndromeInfusion reactionsCD25 expressionDenileukin diftitoxMycosis fungoidesStage diseaseHepatic transaminasesMechanism of actionT cellsIL-2Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study.
Emu B, Kumar P, Mills A, Berhe M, Cash B, Kuo K, Anstett K. Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2025 PMID: 40465394, DOI: 10.1097/qai.0000000000003699.Peer-Reviewed Original ResearchMultidrug-resistant HIV-1Treatment-emergent adverse eventsCD4+ cell countMultidrug resistanceHIV-1Viral loadTreatment optionsDiscontinuations due to treatment-emergent adverse eventsSuppression of viral replicationSafety of long-term useCell countEffective suppression of viral replicationOptimized background regimenTreatment-experienced patientsBaseline to weekPoor clinical outcomesResistant HIV-1Exposure to drugsStudy initiationBackground regimenLong-term useOpen-labelRNA copies/mlPatterns of resistanceMechanism of actionImplementation of a novel interdisciplinary pharmacology curriculum in a hematology/oncology fellowship program.
Forman R, Kwaramba T, Shamilov R, Goldberg S, Lee A, Srikumar T. Implementation of a novel interdisciplinary pharmacology curriculum in a hematology/oncology fellowship program. Journal Of Clinical Oncology 2025, 43: 9028-9028. DOI: 10.1200/jco.2025.43.16_suppl.9028.Peer-Reviewed Original ResearchMechanism of actionCase-basedFellowship programsCancer-directed therapyDrug mechanism of actionTreatment decision makingDosing considerationsPharmacology curriculumToxicity managementTreatment optionsPatient counselingInterdisciplinary patient careLearning science principlesCancer therapeuticsPre-post designCase-based formatPost-lecture surveysThematic qualitative analysisActive learningDrug mechanismsCase-based approachDisease typePost-survey respondentsCase-based curriculumPancreatic β-cell apoptosis caused by apolipoprotein C3-rich low-density lipoprotein is attenuated by kansuinine A through oxidative stress inhibition
Lulji Taraqaz B, Hsu Y, Tsai P, Li Y, Chen F, Yang W, Shen M. Pancreatic β-cell apoptosis caused by apolipoprotein C3-rich low-density lipoprotein is attenuated by kansuinine A through oxidative stress inhibition. Biomedicine & Pharmacotherapy 2025, 187: 118066. PMID: 40262236, DOI: 10.1016/j.biopha.2025.118066.Peer-Reviewed Original ResearchConceptsB cell apoptosisRat pancreatic B-cellsLow-density lipoproteinPathway analysisSignaling pathwayOxidative stressApoptosisImproved cell viabilityRIN-m5FB cellsLectin-like oxidized low-density lipoprotein receptor-1Pancreatic B-cellsHigh-fat dietCell viabilityInsulin toleranceAntiapoptotic propertiesKansuinine AMitigated apoptosisMechanism of actionMolecular dockingStress inhibitionPathwayLow-density lipoprotein receptor-1Improved glucoseHigh-fat4-Anilinoquinolinylchalcone derivatives mediate antifibrotic effects through ERK/MRTF—a signaling pathway crosstalk
Selvam P, Tseng C, Wang C, Sun Y, Chen Y, Kao Y, Dahms H, Cheng C. 4-Anilinoquinolinylchalcone derivatives mediate antifibrotic effects through ERK/MRTF—a signaling pathway crosstalk. Environmental Science And Pollution Research 2025, 32: 11685-11696. PMID: 40234319, DOI: 10.1007/s11356-025-36382-8.Peer-Reviewed Original ResearchConceptsSide effectsAbnormal liver functionAnti-fibrosisSevere side effectsGroup of drugsAnti-inflammatory responseHuman immune systemSkin rashGenitourinary cancersMechanism of actionAntifibrotic effectsBreast cancerScreened 6Immunomodulatory qualitiesLiver functionPharmacological profileImmune systemSignaling pathwaySignaling pathway crosstalkQuinolone analoguesCancerAnti-cancerDerivativesBleedingRashPeriods of susceptibility for associations between phthalate exposure and preterm birth: Results from a pooled analysis of 16 US cohorts
Friedman A, Welch B, Keil A, Bloom M, Braun J, Buckley J, Dabelea D, Factor-Litvak P, Meeker J, Michels K, Padmanabhan V, Starling A, Weinberg C, Aalborg J, Alshawabkeh A, Barrett E, Binder A, Bradman A, Bush N, Calafat A, Cantonwine D, Christenbury K, Cordero J, Engel S, Eskenazi B, Harley K, Hauser R, Herbstman J, Holland N, James-Todd T, Jukic A, Lanphear B, McElrath T, Messerlian C, Newman R, Nguyen R, O'Brien K, Rauh V, Redmon J, Rich D, Rosen E, Sathyanarayana S, Schmidt R, Sparks A, Swan S, Wang C, Watkins D, Weinberger B, Wenzel A, Wilcox A, Yolton K, Zhang Y, Zota A, Ferguson K. Periods of susceptibility for associations between phthalate exposure and preterm birth: Results from a pooled analysis of 16 US cohorts. Environment International 2025, 198: 109392. PMID: 40132438, PMCID: PMC12021553, DOI: 10.1016/j.envint.2025.109392.Peer-Reviewed Original ResearchUrinary phthalate metabolite concentrationsPreterm birthPhthalate metabolite concentrationsGeneralized estimating equationsPhthalate metabolitesOdds ratioMono (2-ethylhexyl) phthalateUS cohortAssociation of preterm birthPhthalate exposureAssociated with preterm birthAssociated with odds ratiosInterquartile range increaseMetabolite concentrationsIndividual-level dataLogistic regression modelsThird trimesterTrimester-specific associationsMechanism of actionPretermPeriod of susceptibilityTime of exposurePooled analysisTrimesterTrimester exposureTargeting the SARS-CoV-2 reservoir in long COVID
Proal A, Aleman S, Bomsel M, Brodin P, Buggert M, Cherry S, Chertow D, Davies H, Dupont C, Deeks S, Ely E, Fasano A, Freire M, Geng L, Griffin D, Henrich T, Hewitt S, Iwasaki A, Krumholz H, Locci M, Marconi V, Mehandru S, Muller-Trutwin M, Painter M, Pretorius E, Price D, Putrino D, Qian Y, Roan N, Salmon D, Tan G, VanElzakker M, Wherry E, Van Weyenbergh J, Yonker L, Peluso M. Targeting the SARS-CoV-2 reservoir in long COVID. The Lancet Infectious Diseases 2025, 25: e294-e306. PMID: 39947217, PMCID: PMC12151306, DOI: 10.1016/s1473-3099(24)00769-2.Peer-Reviewed Original ResearchSARS-CoV-2Duration of treatmentPotential combination approachSARS-CoV-2 persistenceSARS-CoV-2 infectionPost hoc analysisHIV reservoirHepatitis CMechanism of actionPatient subgroupsInterpretation of trialsDebilitating disease statesPrecision oncologyMonoclonal antibodiesGrowing body of evidenceBody of evidenceEffects of psychedelics on opioid use disorder: a scoping review of preclinical studies
Pulido-Saavedra A, Oliva H, Prudente T, Kitaneh R, Nunes E, Fogg C, Funaro M, Weleff J, Nia A, Angarita G. Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies. Cellular And Molecular Life Sciences 2025, 82: 49. PMID: 39833376, PMCID: PMC11747050, DOI: 10.1007/s00018-024-05519-2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsOpioid use disorderUse disorderPreclinical studiesClinical studiesReview of preclinical studiesConditioned place preferenceOpioid self-administrationEffects of psychedelicsPreclinical in vivo studiesOpioid use disorder treatmentFrequency of administrationPlace preferencePotential therapeutic effectsSelf-administrationWithdrawal symptomsPreclinical findingsMechanism of actionSafety profilePain studiesPsychedelicsMethodological quality assessmentClinical evidenceCardiovascular riskOpioidWeb of Science
2024
Psilocybin: From Psychiatric Pariah to Perceived Panacea
Fonzo G, Wolfgang A, Barksdale B, Krystal J, Carpenter L, Kraguljac N, Grzenda A, McDonald W, Widge A, Rodriguez C, Nemeroff C. Psilocybin: From Psychiatric Pariah to Perceived Panacea. American Journal Of Psychiatry 2024, 182: 54-78. PMID: 39741437, PMCID: PMC11694823, DOI: 10.1176/appi.ajp.20230682.Peer-Reviewed Original ResearchConceptsPsychiatric disordersTreatment of obsessive-compulsiveTreatment of psychiatric disordersTreatment of MDDSubstance use disordersEvidence-based treatmentsObsessive-compulsiveDepressive disorderEvidence basePsychiatric treatmentExpectancy effectsRandomized controlled trialsPsilocybinPredictors of responseDiverse sampleMechanism of actionDisordersHead-to-head comparisonsEnglish-language articlesKnowledge of mechanisms of actionOpen-labelClinical responseDosing considerationsImproved blindingCancer diagnosisPhytochemical compounds for treating hyperuricemia associated with gout: a systematic review
Chenchula S, Ghanta M, Alhammadi M, Mohammed A, Anitha K, Nuthalapati P, Raju G, Huh Y, Bhaskar L. Phytochemical compounds for treating hyperuricemia associated with gout: a systematic review. Naunyn-Schmiedeberg's Archives Of Pharmacology 2024, 398: 4779-4801. PMID: 39636406, DOI: 10.1007/s00210-024-03686-4.Peer-Reviewed Original ResearchMechanistic Insights of Gamma Sensory Stimulation: CSF Proteomic Analyses Reveal Changes in Myelin and Synaptic Proteins
Shpokayte M, Pandey K, Singer A, Doung D, Lah J, Levey A, Seyfried N, Malchano Z, Kern R, Hajos M. Mechanistic Insights of Gamma Sensory Stimulation: CSF Proteomic Analyses Reveal Changes in Myelin and Synaptic Proteins. Alzheimer's & Dementia 2024, 20: e087390. PMCID: PMC11715388, DOI: 10.1002/alz.087390.Peer-Reviewed Original ResearchCell surface receptorsAlzheimer's diseaseSurface receptorsCo-expression modulesDifferential expression analysisAD-related pathologyContext of ADProteome databasePost-synaptic densityProteomic analysisExpression analysisSynaptic proteinsCerebrospinal fluid proteomeCerebrospinal fluidProteinSignificance thresholdMyelin-related proteinsSynaptic regulationMechanism of actionSensory stimulationCellsPrecursor cellsRegulationCerebrospinal fluid samplesCerebrospinal fluid proteinNovel Pharmacologic and Other Somatic Treatment Approaches for Posttraumatic Stress Disorder in Adults: State of the Evidence
Sippel L, Hamblen J, Kelmendi B, Alpert J, Carpenter L, Grzenda A, Kraguljac N, McDonald W, Rodriguez C, Widge A, Nemeroff C, Schnurr P, Holtzheimer P, Biomarkers and Treatments T. Novel Pharmacologic and Other Somatic Treatment Approaches for Posttraumatic Stress Disorder in Adults: State of the Evidence. American Journal Of Psychiatry 2024, 181: 1045-1058. PMID: 39616450, DOI: 10.1176/appi.ajp.20230950.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderStress disorderPathophysiology of posttraumatic stress disorderNon-trauma-focused psychotherapyTrauma-focused psychotherapySomatic treatment approachesEvidence-based treatmentsAntidepressant medicationSomatic treatmentsPsychiatric disordersSomatic interventionsTranscranial magnetic stimulationPsychotherapyMagnetic stimulationTreatment approachesDisordersRecommended first-line treatmentAdultsFirst-line treatmentMedicationMechanism of actionMonotherapy strategySalienceSpecific treatmentEvidenceProceedings from an international consensus meeting on ablation in urogenital diseases
Iezzi R, Contegiacomo A, De Filippis A, Gunn A, Atwell T, Mcclure T, Jing Z, Posa A, Scrofani A, Maresca A, Madoff D, Goldberg S, Kelekis A, Filippiadis D, Sala E, Ahmed M. Proceedings from an international consensus meeting on ablation in urogenital diseases. Insights Into Imaging 2024, 15: 267. PMID: 39514046, PMCID: PMC11549275, DOI: 10.1186/s13244-024-01841-2.Peer-Reviewed Original ResearchInternational Consensus MeetingAblation techniqueIntermediate-risk prostate cancerImage-guided ablation techniquesPreoperative surgical riskManagement of oncological diseasesRenal cell carcinomaConsensus meetingTraditional surgical treatmentGenitourinary tract diseaseFibroid SymptomCell carcinomaProstate cancerSurgical riskAblation therapyImprove patient outcomesTumor managementSurgical treatmentMechanism of actionEffective alternativeTherapeutic alternativeSite of applicationEffective treatmentUrogenital diseasesOncological diseasesShifting the paradigm of type 1 diabetes: a narrative review of disease-modifying therapies
O’Donovan A, Gorelik S, Nally L. Shifting the paradigm of type 1 diabetes: a narrative review of disease-modifying therapies. Frontiers In Endocrinology 2024, 15: 1477101. PMID: 39568817, PMCID: PMC11576206, DOI: 10.3389/fendo.2024.1477101.Peer-Reviewed Original ResearchDisease modifying therapiesStages of T1DFood and Drug AdministrationType 1 diabetesLong-term insulin dependenceDestruction of pancreatic beta cellsModifying therapiesDiagnosis of type 1 diabetesClinical diagnosis of T1DClinical diseasePathogenesis of T1DDetection of autoantibodiesDiagnosis of T1DNarrative reviewSymptoms of hyperglycemiaPancreatic beta cellsMechanism of actionAutoimmune conditionsInsulin-dependentPublished trialsGlycemic changesDrug AdministrationInsulin deficiencyTherapyClinical diagnosisPARG inhibition induces nuclear aggregation of PARylated PARP1
Paradkar S, Purcell J, Cui A, Friedman S, Noronha K, Murray M, Sundaram R, Bindra R, Jensen R. PARG inhibition induces nuclear aggregation of PARylated PARP1. Structure 2024, 32: 2083-2093.e5. PMID: 39406247, DOI: 10.1016/j.str.2024.09.006.Peer-Reviewed Original ResearchJAK Inhibitors as Immunomodulators
Peterson D, Damsky W, King B. JAK Inhibitors as Immunomodulators. 2024, 57-71. DOI: 10.1007/978-3-031-66590-5_5.Peer-Reviewed Original ResearchCT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease
Lizama B, Williams C, North H, Pandey K, Duong D, Di V, Mecca A, Blennow K, Zetterberg H, Levey A, Grundman M, van Dyck C, Caggiano A, Seyfried N, Hamby M. CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease. Alzheimer's & Dementia 2024, 20: 6860-6880. PMID: 39166791, PMCID: PMC11485314, DOI: 10.1002/alz.14152.Peer-Reviewed Original ResearchVolumetric magnetic resonance imagingMagnetic resonance imagingPharmacodynamic biomarkersMeta-analysisClinical developmentCerebrospinal fluidPhase 2 clinical trialResonance imagingAlzheimer's diseaseMechanism of actionClinical trialsTandem mass tag-mass spectrometryClinical cohortMild to moderate ADCandidate biomarkersCT1812CohortBiomarker signaturesBiomarkersProteomic findingsUnbiased analysisNetwork analysisAmyloid-betaSynaptic biologyBiological impactEvolving Concepts in Pathophysiology, Screening, and Prevention of Type 1 Diabetes: Report of Diabetes Mellitus Interagency Coordinating Committee Workshop.
Greenbaum C, Nepom G, Wood-Heickman L, Wherrett D, DiMeglio L, Herold K, Krischer J. Evolving Concepts in Pathophysiology, Screening, and Prevention of Type 1 Diabetes: Report of Diabetes Mellitus Interagency Coordinating Committee Workshop. Diabetes 2024, 73: 1780-1790. PMID: 39167668, PMCID: PMC11493760, DOI: 10.2337/dbi24-0020.Peer-Reviewed Original ResearchConceptsType 1 diabetesClinical trialsType 1 Diabetes TrialNetEtiology of type 1 diabetesImmune Tolerance NetworkFood and Drug AdministrationU.S. Food and Drug AdministrationNational Institute of DiabetesDigestive and Kidney DiseasesMultiple immune pathwaysDisease-modifying therapiesMechanism of actionTherapeutic responsePrognostic markerKidney diseaseDrug AdministrationTrialNetClinical diagnosisImmune pathwaysDiabetesTeplizumabRegulatory approvalClinical carePathophysiologyDiseasePediatric cutaneous Crohn disease: A case series of 89 patients and review
McKay G, Liu L, Shaw K, Shakshouk H, Murphy M, Damsky W, Ortega‐Loayza A, Caplan A, Arkin L, Shields B. Pediatric cutaneous Crohn disease: A case series of 89 patients and review. Pediatric Dermatology 2024, 41: 807-813. PMID: 39011834, PMCID: PMC11949095, DOI: 10.1111/pde.15689.Peer-Reviewed Original ResearchBiologic therapyPediatric patientsCrohn's diseaseMetastatic Crohn's diseaseInterleukin-12/23 inhibitorsCutaneous granulomatous inflammationIntestinal Crohn's diseaseDiscordant therapyTNF blockadeOral corticosteroidsInterleukin-12/23Dual therapyRetrospective reviewPediatric casesCutaneous CDMechanism of actionPatient demographicsCase seriesChart reviewClinical characteristicsPartial clearanceGranulomatous inflammationCase of CCDSmall molecule inhibitorsCutaneous disease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply